Collectionner le produit
Détails du produit
Product Specifications
Assay TypeIndirect-ELISAAnalyteAnti-CD28 AntibodyFormat96T (8×12 strips)Reactivity/Regulatory StatusRUOSensitivity≤0.078 ng/mLStandard Curve Range0.078 ng/mL-2.5 ng/mLAssay Time2 hr 20 minSuitable Sample TypeFor the detection of anti-CD28 antibody in Bioprocess manufacturing applicationsSample volume100 μLProduct Overview
Anti-CD28 Antibody Indirect ELISA Kit (Residue Testing) is based on the Indirect-ELISA method and is used to detect and quantitatively determine anti-CD28 antibody residues in cell therapy products. It is designed to provide a reliable solution for cell therapy product quality assessment during drug development and CMC quality control stages.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Materials Provided
IDComponentsSizeCRS014-C01Pre-coated Human CD28 Microplate1 plate (8×12 strips)CRS014-C02Anti-CD28 Antibody Standard20 μgCRS014-C03HRP-Goat anti-Mouse IgG10 μgCRS014-C0410xWashing Buffer50 mLCRS014-C052xDilution Buffer50 mLCRS014-C06Substrate Solution12 mLCRS014-C07Stop Solution7 mLACRO Quality Management System
Les clients ont également consulté
Affichage des données
Typical Data
Please refer to DS document for the assay protocol.
Detection of Monoclonal Anti-CD28 Antibody titer by indirect-ELISA Assay.
Immobilized Human CD28 can bind Anti-CD28 Antibody. Detection was performed using HRP-Goat anti-Mouse IgG with sensitivity of 0.16 ng/mL (QC tested).
Avis des utilisateurs Publier un commentaire
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
T-cell-specific surface glycoprotein CD28
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
31 Détails
- Étape de développement la plus élevée：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
